Both CD20 and FcγRIIB staining were reduced on DLBCL recovered from rituximab-treated compared to control-treated spheroids (Figure 8D), confirming that Rituximab was able to access spheroids and interact with the primary DLBCL cells within them. The gene discussed is FCGR2B; the disease is diffuse large B-cell lymphoma.